{"id":1016358,"date":"2026-11-02T16:10:52","date_gmt":"2026-11-02T21:10:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-report-q3-2026-financial-results-on-november-9-2026\/"},"modified":"2026-11-02T16:10:52","modified_gmt":"2026-11-02T21:10:52","slug":"xenon-to-report-q3-2026-financial-results-on-november-9-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-report-q3-2026-financial-results-on-november-9-2026\/","title":{"rendered":"Xenon to Report Q3 2026 Financial Results on November 9, 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p>VANCOUVER, BC and BOSTON, MA, Nov.  02, 2026  (GLOBE NEWSWIRE) &#8212; Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced it will report its third quarter 2026 financial results and provide a business update after the close of U.S. financial markets on Monday, November 9, 2026.<\/p>\n<p>\n        <strong>Company Presentation Details:<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>Date:<\/strong>\n          <\/td>\n<td style=\"vertical-align: top\">Monday, November 9, 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>Time:<\/strong>\n          <\/td>\n<td style=\"vertical-align: top\">4:30pm EST (2:30pm PCT)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>Webcast:<\/strong>\n          <\/td>\n<td style=\"vertical-align: top\">\n            <a href=\"https:\/\/edge.media-server.com\/mmc\/p\/obfgtuc8\/\" rel=\"nofollow\" target=\"_blank\">Pre-register here<\/a><br \/>\n            \n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>Dial-In: <\/strong><br \/>\n            \n          <\/td>\n<td style=\"vertical-align: top\">(800) 715-9871 toll-free or (646) 307-1963 for international callers<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>Conference ID:<\/strong>\n          <\/td>\n<td style=\"vertical-align: top\">8984105<\/td>\n<\/tr>\n<\/table>\n<p>\n        <br \/>A live webcast of the company presentation will be available on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=I_0VtFYRn7ESVepIs3HWbxKCdJQi9eSkDVcVHrqAqdBUifQF6iFIUqBxnrqto7Wht6uT11Yk3DKy3DSKfp075adV5CZP2fOk_KbAtR1rR4v1wWOKTQt0gtlCjWPmLhICt7bEhY9g9wONJTsrHX7BSg==\" rel=\"nofollow\" target=\"_blank\">Investors<\/a> section of Xenon&#8217;s website and posted for replay following the event. The above-mentioned dates and times are subject to change.<\/p>\n<p>\n        <strong><br \/>\n          <u>About Xenon Pharmaceuticals Inc.<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon\u2019s lead molecule, azetukalner, is a novel, potent K<sub>V<\/sub>7 potassium channel opener in late-stage clinical development for the treatment of epilepsy, major depressive disorder and bipolar depression. Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including K<sub>V<\/sub>7 and Na<sub>V<\/sub>1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jevuboHsFCrE05VyOKAXHlz-5v0bKwedc91Ko4blpH8Kg9vOtZ1cAmWMXEkHgXv4NwCJ1maJVM24eq_FfnyGY2UyYsKnraa1u18svsoEAVk=\" rel=\"nofollow\" target=\"_blank\">www.xenon-pharma.com<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MZGB1490yfCSARZjIZMHv0CAH1z9cE-DloB9vX8SdFLDkc9iN2yEHjfNFpIvlVcI_tJoNng4IArKNAf78yeGyAkGBG3RIRi_tcaMaZB-E2Q=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Qu5411Lxu1NySd1aWBc_2lozmsisdu7Fnb2UXIMcIFtK0IHK19r1POd5SwYomBNsd-vjZBlpdZxpO3mV-jc1VQ==\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p>Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada and elsewhere. All other trademarks belong to their respective owner.<\/p>\n<p>\n        <strong><br \/>\n          <u>Contacts:<\/u><br \/>\n        <\/strong>\u00a0<br \/><em>For Investors:<\/em><br \/>Laura Perry\/Emily Huang<br \/>Argot Partners<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CVdOeuuO9WK--ZKKT_TMbKzy4CcSU4S_HTB-Oj-wlOFgISs_zb67AgH-I45BMeRSC6AhQ_d0rpKTQcD90Ep_AtrjMJ3LA0nVJPTUdqmol94=\" rel=\"nofollow\" target=\"_blank\">Xenon@argotpartners.com<\/a><\/p>\n<p>\n        <em>For Media:<\/em><br \/>\n        <br \/>Colleen Alabiso<br \/>Senior Vice President, Corporate Affairs<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iRpwhxmfJ7M_AHvS8eYVCaZ7Tq9woVOTfcdORigXgW8EAu-cHA7ccUtsM_Sv3tCo2ltoBoJTT1ygQIkMsTM5WrJiXSzzCckKtLTYhPXsErM=\" rel=\"nofollow\" target=\"_blank\">media@xenon-pharma.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2ODM1NiM3OTQwNDAyIzIwMTEzODA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NmM3NjAxZTQtYzZjYS00ZjRjLWJiNmItNTEwYTU1YzJiZTNiLTEwMjI5NTMtMjAyNi0xMS0wMi1lbg==\/tiny\/Xenon-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>VANCOUVER, BC and BOSTON, MA, Nov. 02, 2026 (GLOBE NEWSWIRE) &#8212; Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced it will report its third quarter 2026 financial results and provide a business update after the close of U.S. financial markets on Monday, November 9, 2026. Company Presentation Details: Date: Monday, November 9, 2026 Time: 4:30pm EST (2:30pm PCT) Webcast: Pre-register here Dial-In: (800) 715-9871 toll-free or (646) 307-1963 for international callers Conference ID: 8984105 A live webcast of the company presentation will be available on the Investors section of Xenon&#8217;s website and posted for replay following the event. The above-mentioned dates and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-report-q3-2026-financial-results-on-november-9-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Xenon to Report Q3 2026 Financial Results on November 9, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1016358","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Xenon to Report Q3 2026 Financial Results on November 9, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-report-q3-2026-financial-results-on-november-9-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Xenon to Report Q3 2026 Financial Results on November 9, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"VANCOUVER, BC and BOSTON, MA, Nov. 02, 2026 (GLOBE NEWSWIRE) &#8212; Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced it will report its third quarter 2026 financial results and provide a business update after the close of U.S. financial markets on Monday, November 9, 2026. Company Presentation Details: Date: Monday, November 9, 2026 Time: 4:30pm EST (2:30pm PCT) Webcast: Pre-register here Dial-In: (800) 715-9871 toll-free or (646) 307-1963 for international callers Conference ID: 8984105 A live webcast of the company presentation will be available on the Investors section of Xenon&#8217;s website and posted for replay following the event. The above-mentioned dates and &hellip; Continue reading &quot;Xenon to Report Q3 2026 Financial Results on November 9, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-report-q3-2026-financial-results-on-november-9-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-02T21:10:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2ODM1NiM3OTQwNDAyIzIwMTEzODA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-to-report-q3-2026-financial-results-on-november-9-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-to-report-q3-2026-financial-results-on-november-9-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Xenon to Report Q3 2026 Financial Results on November 9, 2026\",\"datePublished\":\"2026-11-02T21:10:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-to-report-q3-2026-financial-results-on-november-9-2026\\\/\"},\"wordCount\":284,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-to-report-q3-2026-financial-results-on-november-9-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg2ODM1NiM3OTQwNDAyIzIwMTEzODA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-to-report-q3-2026-financial-results-on-november-9-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-to-report-q3-2026-financial-results-on-november-9-2026\\\/\",\"name\":\"Xenon to Report Q3 2026 Financial Results on November 9, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-to-report-q3-2026-financial-results-on-november-9-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-to-report-q3-2026-financial-results-on-november-9-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg2ODM1NiM3OTQwNDAyIzIwMTEzODA=\",\"datePublished\":\"2026-11-02T21:10:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-to-report-q3-2026-financial-results-on-november-9-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-to-report-q3-2026-financial-results-on-november-9-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-to-report-q3-2026-financial-results-on-november-9-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg2ODM1NiM3OTQwNDAyIzIwMTEzODA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg2ODM1NiM3OTQwNDAyIzIwMTEzODA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-to-report-q3-2026-financial-results-on-november-9-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Xenon to Report Q3 2026 Financial Results on November 9, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Xenon to Report Q3 2026 Financial Results on November 9, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-report-q3-2026-financial-results-on-november-9-2026\/","og_locale":"en_US","og_type":"article","og_title":"Xenon to Report Q3 2026 Financial Results on November 9, 2026 - Market Newsdesk","og_description":"VANCOUVER, BC and BOSTON, MA, Nov. 02, 2026 (GLOBE NEWSWIRE) &#8212; Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced it will report its third quarter 2026 financial results and provide a business update after the close of U.S. financial markets on Monday, November 9, 2026. Company Presentation Details: Date: Monday, November 9, 2026 Time: 4:30pm EST (2:30pm PCT) Webcast: Pre-register here Dial-In: (800) 715-9871 toll-free or (646) 307-1963 for international callers Conference ID: 8984105 A live webcast of the company presentation will be available on the Investors section of Xenon&#8217;s website and posted for replay following the event. The above-mentioned dates and &hellip; Continue reading \"Xenon to Report Q3 2026 Financial Results on November 9, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-report-q3-2026-financial-results-on-november-9-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-02T21:10:52+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2ODM1NiM3OTQwNDAyIzIwMTEzODA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-report-q3-2026-financial-results-on-november-9-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-report-q3-2026-financial-results-on-november-9-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Xenon to Report Q3 2026 Financial Results on November 9, 2026","datePublished":"2026-11-02T21:10:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-report-q3-2026-financial-results-on-november-9-2026\/"},"wordCount":284,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-report-q3-2026-financial-results-on-november-9-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2ODM1NiM3OTQwNDAyIzIwMTEzODA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-report-q3-2026-financial-results-on-november-9-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-report-q3-2026-financial-results-on-november-9-2026\/","name":"Xenon to Report Q3 2026 Financial Results on November 9, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-report-q3-2026-financial-results-on-november-9-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-report-q3-2026-financial-results-on-november-9-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2ODM1NiM3OTQwNDAyIzIwMTEzODA=","datePublished":"2026-11-02T21:10:52+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-report-q3-2026-financial-results-on-november-9-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-report-q3-2026-financial-results-on-november-9-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-report-q3-2026-financial-results-on-november-9-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2ODM1NiM3OTQwNDAyIzIwMTEzODA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2ODM1NiM3OTQwNDAyIzIwMTEzODA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-report-q3-2026-financial-results-on-november-9-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Xenon to Report Q3 2026 Financial Results on November 9, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1016358","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1016358"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1016358\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1016358"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1016358"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1016358"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}